Hepatitis C News

A range of interventions improved testing, linkage to care and treatment initiation in patients with hepatitis C, according to a study published in The Lancet Gastroenterology & Hepatology.

Approximately 1.2 million people in the United States initiated treatment with direct-acting antivirals for hepatitis C virus infection between 2014 and 2020, more than half of whom were baby boomers, according to a study.

Universal screening for hepatitis C virus detected more infections in pregnant people, as well as transmission to infants, according to a presenter at the Conference on Retroviruses and Opportunistic Infections.

Healio presents the following report on the top 10 hepatology peer-tested articles from 2021.

Among patients treated with sofosbuvir and velpatasvir for hepatitis C virus, the minimal monitoring approach achieved sustained virological response similar to standard monitoring, according to research.

Novel hepatitis B virus RNA and HBV core-related antigen blood assays revealed continued disease activity despite apparently suppressed virus replication among patients dosed with antiviral therapy for HBV and HIV coinfection.

Simplifying the hepatitis C virus treatment process is essential to improving care among vulnerable populations, particularly people who inject drugs.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories from 2021.

Bulevirtide improved quality of life measures among patients treated for chronic hepatitis D virus, Maria Buti, MD, PhD, of the Hospital Universiario Valle Hebron, told Healio Gastroenterology.

Hepatitis D, in hepatitis B surface antigen-positive individuals, may remain undiagnosed due to lack of testing, particularly in primary care settings, according to a poster.